ÂÜÀòÂÒÂ×

Paolo Vicini joined Confo Therapeutics as CDO in 2020.

Over the last 20 years, Dr. Vicini has worked as an expert in pharmacology and drug development in the international biopharmaceutical industry and academia. He held positions including Vice President Development Sciences at Kymab Ltd. in Cambridge U.K and Senior Director of Translational Sciences, Clinical Pharmacology, Pharmacometrics and Drug Metabolism and Pharmacokinetics at MedImmune’s Cambridge U.K. site. Dr. Vicini was a Research Fellow, Biotherapeutics and Translational Research, with Pharmacokinetics, Dynamics and Metabolism at Pfizer Worldwide Research and Development in California for seven years. Prior to that, he was a faculty member with the Department of Bioengineering, University of Washington, Seattle, Washington (US).

Dr. Vicini has received multiple honors, is a Fellow of the American Association of Pharmaceutical Scientists and a member of several professional organizations. He has over 140 publications in diverse areas including oncology-targeted agents, diabetes, immunotherapy and immunogenicity of biotherapeutics, dose optimization as well as pharmacometrics and systems pharmacology.

Dr. Vicini obtained his PhD in Bioengineering from the Polytechnic of Milan and the University of Padova (Italy) and finished his MBA in 2014 from the University of Southern California in Los Angeles (US).